Compare ANIP & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | ENVX |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | ANIP | ENVX |
|---|---|---|
| Price | $79.59 | $8.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $105.83 | $17.14 |
| AVG Volume (30 Days) | 409.7K | ★ 6.2M |
| Earning Date | 11-07-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $826,880,000.00 | $30,273,000.00 |
| Revenue This Year | $44.06 | $36.91 |
| Revenue Next Year | $9.06 | $117.80 |
| P/E Ratio | $46.26 | ★ N/A |
| Revenue Growth | ★ 48.87 | 45.98 |
| 52 Week Low | $52.74 | $5.27 |
| 52 Week High | $99.50 | $16.49 |
| Indicator | ANIP | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 48.59 |
| Support Level | $76.69 | $7.21 |
| Resistance Level | $80.29 | $8.89 |
| Average True Range (ATR) | 2.41 | 0.48 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 37.74 | 53.80 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.